Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis

被引：51
作者：
Jang, Min Kyeong [1 ,2 ]
Park, Chang [2 ]
Hong, Susan [1 ,3 ]
Li, Hongjin [1 ,2 ]
Rhee, Esther [1 ,4 ]
Doorenbos, Ardith Z. [1 ,2 ]
机构：
[1] Univ Illinois, Ctr Canc, 818 S Wolcott Ave, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Nursing, Chicago, IL USA
[3] Univ Illinois, Coll Med, Dept Med, Div Acad Internal Med & Geriatr, Chicago, IL USA
[4] Univ Illinois, Coll Med, Dept Med, Div Acad Internal Med, Chicago, IL USA
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 05期
基金：
美国国家卫生研究院;
关键词：
Muscle mass loss; sarcopenia; cancer; skeletal muscle index; meta-analysis; review; CANCER-RELATED FATIGUE; PROGNOSTIC VALUE; HEPATOCELLULAR-CARCINOMA; SARCOPENIA; PREVALENCE; RECURRENCE; IMPACT; ASSOCIATION; GASTRECTOMY; ETHNICITY;
D O I：
10.21873/anticanres.14210
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. Materials and Methods: We searched primary original research published through October 2019 in four databases: MEDLINE via PubMed, Scopus, CINAHL, and Embase. Results: Fifteen studies were included, 60% published in the past 2 years (2018-2019). Advanced non-small cell lung cancer was the most frequently reported cancer, and overall survival the most often identified key related factor. Mean difference in skeletal muscle index during chemotherapy was 2.72 (95%CI=1.77-3.67, p=0.00), with muscle loss in males (4.52, 95%CI=3.34-5.71, p=0.00) about 1.6 times higher than that in females (2.86, 95%CI=0.81-4.92, p=0.01). Conclusion: Oncologists should recognize sex- specific differences in skeletal muscle mass loss during chemotherapy and consider adjusting treatment accordingly.
引用
收藏
页码：2409 / 2418
页数：10
相关论文
共 43 条
  • [1] Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
    Batsis, John A.
    Villareal, Dennis T.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2018, 14 (09) : 513 - 537
  • [2] Cancer-Related Fatigue, Version 2.2015
    Berger, Ann M.
    Mooney, Kathi
    Alvarez-Perez, Amy
    Breitbart, William S.
    Carpenter, Kristen M.
    Cella, David
    Cleeland, Charles
    Dotan, Efrat
    Eisenberger, Mario A.
    Escalante, Carmen P.
    Jacobsen, Paul B.
    Jankowski, Catherine
    LeBlanc, Thomas
    Ligibel, Jennifer A.
    Loggers, Elizabeth Trice
    Mandrell, Belinda
    Murphy, Barbara A.
    Palesh, Oxana
    Pirl, William F.
    Plaxe, Steven C.
    Riba, Michelle B.
    Rugo, Hope S.
    Salvador, Carolina
    Wagner, Lynne I.
    Wagner-Johnston, Nina D.
    Zachariah, Finly J.
    Bergman, Mary Anne
    Smith, Courtney
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (08): : 1012 - 1039
  • [3] Castaneda C, 2005, ETHNIC DIS, V15, P664
  • [4] Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Chang, Ke-Vin
    Chen, Jin-De
    Wu, Wei-Ting
    Huang, Kuo-Chin
    Hsu, Chia-Tzu
    Han, Der-Sheng
    [J]. LIVER CANCER, 2018, 7 (01) : 90 - 103
  • [5] Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
    Cho, Kyoung-Min
    Park, Hyunkyung
    Oh, Do-Youn
    Kim, Tae-Yong
    Lee, Kyung Hun
    Han, Sae-Won
    Im, Seock-Ah
    Kim, Tae-You
    Bang, Yung-Jue
    [J]. ONCOTARGET, 2017, 8 (45) : 79441 - 79452
  • [6] The assessment and impact of sarcopenia in lung cancer: a systematic literature review
    Collins, Jemima
    Noble, Simon
    Chester, John
    Coles, Bernadette
    Byrne, Anthony
    [J]. BMJ OPEN, 2014, 4 (01):
  • [7] Sarcopenia associated with chemotherapy and targeted agents for cancer therapy
    Davis, Mellar P.
    Panikkar, Rajiv
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2019, 8 (01) : 86 - 101
  • [8] Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer
    Griffin, Oonagh M.
    Duggan, Sinead N.
    Ryan, Ronan
    McDermott, Raymond
    Geoghegan, Justin
    Conlon, Kevin C.
    [J]. PANCREATOLOGY, 2019, 19 (06) : 850 - 857
  • [9] Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance
    Guinan, Emer M.
    Doyle, S. L.
    Bennett, A. E.
    O'Neill, L.
    Gannon, J.
    Elliott, J. A.
    O'Sullivan, J.
    Reynolds, J. V.
    Hussey, J.
    [J]. SUPPORTIVE CARE IN CANCER, 2018, 26 (05) : 1569 - 1576
  • [10] CONVINCING EVIDENCE FROM CONTROLLED AND UNCONTROLLED STUDIES ON THE LIPID-LOWERING EFFECT OF A STATIN
    Higgins, Julian
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
12345